Terrie Curran

Board Member

Terrie Curran has served as a member of our board of directors since November 2020. Ms Curran retired in April 2025 from Phathom Pharmaceuticals (Nasdaq: PHAT), a late-clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal diseases, where she served as CEO and president. Prior to this, she was the president, global inflammation and immunology (I&I) franchise and member of the executive committee at Celgene. She joined Celgene in 2013 as head of US commercial operations for the I&I franchise, where she built the organization and led the successful launch of Otezla® for moderate to severe plaque psoriasis. Earlier in her career, Ms Curran served as senior vice president and general manager of global women’s health at Merck & Co. Ms Curran holds both bachelor’s and graduate degrees from the University of Technology Sydney.